September 8, 2020 10:46 AM EDT
News Briefing

News brief­ing: Ex­elix­is rolls the dice with 2 ADC deals tied to $35M cash up­fronts; A rare an­tibi­ot­ic win for promi­nent­ly-backed Spero

John Carroll

Editor & Founder

Jason Mast

Editor

Max Gelman

Senior Editor

Catal­ent’s Red­wood Bio­science sub­sidiary is tak­ing the lead role in de­vel­op­ing AD­Cs for Ex­elix­is $EX­EL. In one of 2 deals an­nounced this morn­ing, Ex­elix­is is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times